Aligos Therapeutics Stock Market Value
| ALGS Stock | USD 26.75 1.03 4.00% |
| Symbol | Aligos |
Aligos Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aligos Therapeutics. If investors know Aligos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aligos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.25) | Revenue Per Share 1.005 | Quarterly Revenue Growth (0.61) | Return On Assets (0.67) | Return On Equity (1.47) |
The market value of Aligos Therapeutics is measured differently than its book value, which is the value of Aligos that is recorded on the company's balance sheet. Investors also form their own opinion of Aligos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aligos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aligos Therapeutics' market value can be influenced by many factors that don't directly affect Aligos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aligos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aligos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aligos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Aligos Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aligos Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aligos Therapeutics.
| 11/03/2024 |
| 12/03/2024 |
If you would invest 0.00 in Aligos Therapeutics on November 3, 2024 and sell it all today you would earn a total of 0.00 from holding Aligos Therapeutics or generate 0.0% return on investment in Aligos Therapeutics over 30 days. Aligos Therapeutics is related to or competes with CytomX Therapeutics, Spero Therapeutics, Instil Bio, NextCure, Assembly Biosciences, Achilles Therapeutics, and Nuvation Bio. Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address ... More
Aligos Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aligos Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aligos Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 9.31 | |||
| Information Ratio | 0.1293 | |||
| Maximum Drawdown | 84.34 | |||
| Value At Risk | (11.21) | |||
| Potential Upside | 25.24 |
Aligos Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aligos Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aligos Therapeutics' standard deviation. In reality, there are many statistical measures that can use Aligos Therapeutics historical prices to predict the future Aligos Therapeutics' volatility.| Risk Adjusted Performance | 0.1163 | |||
| Jensen Alpha | 1.46 | |||
| Total Risk Alpha | (0.12) | |||
| Sortino Ratio | 0.1618 | |||
| Treynor Ratio | 1.14 |
Aligos Therapeutics Backtested Returns
Aligos Therapeutics is risky given 3 months investment horizon. Aligos Therapeutics secures Sharpe Ratio (or Efficiency) of 0.16, which signifies that the company had a 0.16% return per unit of risk over the last 3 months. We were able to analyze and collect data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.86% are justified by taking the suggested risk. Use Aligos Therapeutics Downside Deviation of 9.31, mean deviation of 6.69, and Risk Adjusted Performance of 0.1163 to evaluate company specific risk that cannot be diversified away. Aligos Therapeutics holds a performance score of 12 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.42, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aligos Therapeutics will likely underperform. Use Aligos Therapeutics potential upside, and the relationship between the total risk alpha and kurtosis , to analyze future returns on Aligos Therapeutics.
Auto-correlation | 0.90 |
Excellent predictability
Aligos Therapeutics has excellent predictability. Overlapping area represents the amount of predictability between Aligos Therapeutics time series from 3rd of November 2024 to 18th of November 2024 and 18th of November 2024 to 3rd of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aligos Therapeutics price movement. The serial correlation of 0.9 indicates that approximately 90.0% of current Aligos Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.9 | |
| Spearman Rank Test | 0.86 | |
| Residual Average | 0.0 | |
| Price Variance | 8.26 |
Aligos Therapeutics lagged returns against current returns
Autocorrelation, which is Aligos Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Aligos Therapeutics' stock expected returns. We can calculate the autocorrelation of Aligos Therapeutics returns to help us make a trade decision. For example, suppose you find that Aligos Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Aligos Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Aligos Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Aligos Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Aligos Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Aligos Therapeutics Lagged Returns
When evaluating Aligos Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Aligos Therapeutics stock have on its future price. Aligos Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Aligos Therapeutics autocorrelation shows the relationship between Aligos Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Aligos Therapeutics.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.